drugset / Trial / NCT01529424
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the dose/response pharmacodynamic effects of ISIS ApoC-III Rx vs. Placebo on fasting total apoC-III levels.
Timeline
- Start
- 2012-02
- Primary completion
- 2014-01
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Volanesorsen | Antisense oligonucleotide | 100 mg | Subcutaneous |
| Subject | Volanesorsen | Antisense oligonucleotide | 200 mg | Subcutaneous |
| Subject | Volanesorsen | Antisense oligonucleotide | 300 mg | Subcutaneous |